Search

• GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD

  Media

  GSK announced positive results from comparing umeclidinium to two available bronchodilator treatments when used by patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-new-data-comparing-incruse-ellipta-to-tiotropium-and-glycopyrronium-in-patients-with-copd/

  First published: 20 October 2015

• GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration

  Media

  Shingrix already approved in China for adults aged 50 years and over.

  https://www.gsk.com/en-gb/media/press-releases/regulatory-application-for-shingrix-for-the-prevention-of-shingles-adults-aged-18-and-over-accepted-for-review-in-china/

  First published: 06 February 2024

• GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

  Media

  Data from four randomised phase III studies show that patients on albiglutide, continued to show blood glucose lowering at three years.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-once-weekly-tanzeumeperzan-albiglutide-showing-blood-glucose-lowering-up-to-three-years-in-type-2-diabetes/

  First published: 14 June 2014

• GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over

  Media

  GSK today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ successfully met its primary objective

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-demonstrates-90-efficacy-against-shingles-in-people-70-years-of-age-and-over/

  First published: 27 October 2015

• GSK’s malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa

  Media

  GSK announced that the CHMP of EMA has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-malaria-candidate-vaccine-mosquirix-rts-s-receives-positive-opinion-from-european-regulators-for-the-prevention-of-malaria-in-young-children-in-sub-saharan-africa/

  First published: 24 July 2015

• Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up

  Media

  Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate published today in The Lancet.

  https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-has-demonstrated-efficacy-over-3-4-years-of-follow-up/

  First published: 24 April 2015

• GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

  Media

  GSK announced application to the Japanese MHLW for mepolizumab as add-on maintenance treatment for patients with severe eosinophilic asthma

  https://www.gsk.com/en-gb/media/press-releases/gsk-submits-japan-regulatory-application-for-mepolizumab-in-severe-eosinophilic-asthma/

  First published: 22 May 2015

• Anoro® (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD

  Media

  GSK & THRX announced that the European Commission has granted marketing authorisation for Anoro to relieve symptoms in patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidiniumvilanterol-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/

  First published: 08 May 2014

• Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

  Media

  GSK & THRX announced that JMHLW has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms with COPD

  https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-umeclidiniumvilanterol-gains-approval-in-japan-for-the-treatment-of-copd/

  First published: 04 July 2014

• GSK acquires full ownership of its Indonesian Consumer Healthcare business

  Media

  GSK has acquired full ownership of its Indonesian Consumer Healthcare business

  https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-full-ownership-of-its-indonesian-consumer-healthcare-business/

  First published: 28 March 2014